{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T01:04:50Z","timestamp":1767143090780,"version":"build-2238731810"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T00:00:00Z","timestamp":1649203200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1007\/s40259-022-00527-9","type":"journal-article","created":{"date-parts":[[2022,4,6]],"date-time":"2022-04-06T06:21:12Z","timestamp":1649226072000},"page":"473-485","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Immunotherapy in Gastro-Oesophageal Cancer: Current Practice and the Future of Personalised Therapy"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5466-6447","authenticated-orcid":false,"given":"Mary E.","family":"Booth","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4667-1817","authenticated-orcid":false,"given":"Elizabeth C.","family":"Smyth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,6]]},"reference":[{"key":"527_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"527_CR2","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/nature13480","volume":"513","author":"The Cancer Genome Atlas Research Network","year":"2014","unstructured":"The Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202\u20139.","journal-title":"Nature"},{"key":"527_CR3","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1038\/nm.3850","volume":"21","author":"R Cristescu","year":"2015","unstructured":"Cristescu R, Lee J, Nebozhyn M, Kim K-M, Ting JC, Wong SS, et al. Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. Nat Med. 2015;21:449\u201356.","journal-title":"Nat Med"},{"key":"527_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/nature20805","volume":"541","author":"The Cancer Genome Atlas Research Network","year":"2017","unstructured":"The Cancer Genome Atlas Research Network. Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169\u201375.","journal-title":"Nature"},{"key":"527_CR5","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/S0140-6736(10)61121-X","volume":"376","author":"YJ Bang","year":"2010","unstructured":"Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687\u201397.","journal-title":"Lancet"},{"key":"527_CR6","doi-asserted-by":"publisher","first-page":"4010","DOI":"10.1200\/JCO.2021.39.15_suppl.4010","volume":"39","author":"DVT Catenacci","year":"2021","unstructured":"Catenacci DVT, Kang Y-K, Saeed A, Yamaguchi K, Qin S, Lee K-W, et al. FIGHT: a randomized, double-blind, placebo-controlled, phase II study of bemarituzumab (bema) combined with modified FOLFOX6 in 1L FGFR2b+ advanced gastric\/gastroesophageal junction adenocarcinoma (GC). J Clin Oncol. 2021;39:4010.","journal-title":"J Clin Oncol"},{"key":"527_CR7","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.annonc.2021.02.005","volume":"32","author":"U Sahin","year":"2021","unstructured":"Sahin U, T\u00fcreci \u00d6, Manikhas G, Lordick F, Rusyn A, Vynnychenko I, et al. FAST: a randomised phase II study of zolbetuximab (IMAB362) plus EOX versus EOX alone for first-line treatment of advanced CLDN18.2-positive gastric and gastro-oesophageal adenocarcinoma. Ann Oncol. 2021;32:609\u201319.","journal-title":"Ann Oncol"},{"key":"527_CR8","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1158\/2159-8290.CD-20-1408","volume":"11","author":"DVT Catenacci","year":"2021","unstructured":"Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, et al. Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): a phase II study evaluating an individualized treatment strategy for metastatic disease. Cancer Discov. 2021;11:308\u201325.","journal-title":"Cancer Discov"},{"key":"527_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.immuni.2013.07.012","volume":"39","author":"DS Chen","year":"2013","unstructured":"Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity. 2013;39:1\u201310.","journal-title":"Immunity"},{"key":"527_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.5858\/arpa.2018-0043-OA","volume":"143","author":"K Kulangara","year":"2019","unstructured":"Kulangara K, Zhang N, Corigliano E, Guerrero L, Waldroup S, Jaiswal D, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer. Arch Pathol Lab Med. 2019;143:330\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"527_CR11","doi-asserted-by":"publisher","first-page":"3925","DOI":"10.1158\/1078-0432.CCR-20-2790","volume":"27","author":"M Lei","year":"2021","unstructured":"Lei M, Siemers NO, Pandya D, Chang H, Sanchez T, Harbison C, et al. Analyses of PD-L1 and inflammatory gene expression association with efficacy of nivolumab \u00b1 Ipilimumab in gastric cancer\/gastroesophageal junction cancer. Clin Cancer Res. 2021;27:3925\u201335.","journal-title":"Clin Cancer Res"},{"key":"527_CR12","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1056\/NEJMoa2111380","volume":"386","author":"Y Doki","year":"2022","unstructured":"Doki Y, Ajani JA, Kato K, Xu J, Wyrwicz L, Motoyama S, et al. Nivolumab combination therapy in advanced esophageal squamous-cell carcinoma. N Engl J Med. 2022;386:449\u201362.","journal-title":"N Engl J Med"},{"key":"527_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12935-020-01273-0","volume":"20","author":"M Ye","year":"2020","unstructured":"Ye M, Huang D, Zhang Q, Weng W, Tan C, Qin G, et al. Heterogeneous programmed death-ligand 1 expression in gastric cancer: comparison of tissue microarrays and whole sections. Cancer Cell Int. 2020;20:1\u20138.","journal-title":"Cancer Cell Int"},{"key":"527_CR14","doi-asserted-by":"publisher","first-page":"6453","DOI":"10.1158\/1078-0432.CCR-20-2085","volume":"26","author":"KI Zhou","year":"2020","unstructured":"Zhou KI, Peterson B, Serritella A, Thomas J, Reizine N, Moya S, et al. Spatial and temporal heterogeneity of PD-L1 expression and tumor mutational burden in gastroesophageal adenocarcinoma at baseline diagnosis and after chemotherapy. Clin Cancer Res. 2020;26:6453\u201363.","journal-title":"Clin Cancer Res"},{"key":"527_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40880-017-0226-3","volume":"36","author":"Y Gao","year":"2017","unstructured":"Gao Y, Li S, Xu D, Chen S, Cai Y, Jiang W, et al. Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1\u20134N+M0 gastric adenocarcinoma. Chin J Cancer. 2017;36:1\u201314.","journal-title":"Chin J Cancer"},{"key":"527_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fonc.2019.00136","volume":"9","author":"MC Svensson","year":"2019","unstructured":"Svensson MC, Borg D, Zhang C, Hedner C, Nodin B, Uhl\u00e9n M, et al. Expression of PD-L1 and PD-1 in chemoradiotherapy-na\u00efve esophageal and gastric adenocarcinoma: relationship with mismatch repair status and survival. Front Oncol. 2019;9:1\u201313.","journal-title":"Front Oncol"},{"key":"527_CR17","unstructured":"Merck & Co. Keytruda (pembrolizumab) [package insert]. US Food and Drug Administration. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/125514s096lbl.pdf. [Accessed 16 Feb 2022]."},{"key":"527_CR18","doi-asserted-by":"publisher","first-page":"661","DOI":"10.4143\/crt.2019.718","volume":"52","author":"Y Park","year":"2020","unstructured":"Park Y, Koh J, Na HY, Kwak Y, Lee K-W, Ahn S-H, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer Res Treat. 2020;52:661\u201370.","journal-title":"Cancer Res Treat"},{"key":"527_CR19","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1038\/s41379-021-00823-9","volume":"34","author":"S Ahn","year":"2021","unstructured":"Ahn S, Kyoung-Mee K. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28\u20138 pharmDx assays for responses to immunotherapy. Mod Pathol. 2021;34:1719\u201327.","journal-title":"Mod Pathol"},{"key":"527_CR20","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.jtho.2016.11.2228","volume":"12","author":"FR Hirsch","year":"2017","unstructured":"Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, et al. PD-L1 immunohistochemistry assays for lung cancer: results from phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208\u201322.","journal-title":"J Thorac Oncol"},{"key":"527_CR21","doi-asserted-by":"publisher","first-page":"1302","DOI":"10.1016\/j.jtho.2018.05.013","volume":"13","author":"MS Tsao","year":"2018","unstructured":"Tsao MS, Kerr KM, Kockx M, Beasley MB, Borczuk AC, Botling J, et al. PD-L1 immunohistochemistry comparability study in real-life clinical samples: results of Blueprint Phase 2 Project. J Thorac Oncol. 2018;13:1302\u201311.","journal-title":"J Thorac Oncol"},{"key":"527_CR22","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S1470-2045(18)30739-3","volume":"19","author":"K Shitara","year":"2018","unstructured":"Shitara K, Doi T, Dvorkin M, Mansoor W, Arkenau HT, Prokharau A, et al. Trifluridine\/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncology. 2018;19:1437\u201348.","journal-title":"Lancet Oncology"},{"key":"527_CR23","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017;390:2461\u201371.","journal-title":"Lancet"},{"key":"527_CR24","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1007\/s10120-019-01034-7","volume":"23","author":"L-T Chen","year":"2020","unstructured":"Chen L-T, Satoh T, Ryu M-H, Chao Y, Kato K, Chung HC, et al. A phase 3 study of nivolumab in previously treated advanced gastric or gastroesophageal junction cancer (ATTRACTION-2): 2-year update data. Gastric Cancer. 2020;23:510\u20139.","journal-title":"Gastric Cancer"},{"key":"527_CR25","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1093\/annonc\/mdy264","volume":"29","author":"Y-J Bang","year":"2018","unstructured":"Bang Y-J, Ruiz EY, van Cutsem E, Lee K-W, Wyrwicz L, Schenker M, et al. Phase III, randomised trial of avelumab versus physician\u2019s choice of chemotherapy as third-line treatment of patients with advanced gastric or gastro-oesophageal junction cancer: primary analysis of JAVELIN Gastric 300. Ann Oncol. 2018;29:2052\u201360.","journal-title":"Ann Oncol"},{"key":"527_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S0140-6736(18)31257-1","volume":"392","author":"K Shitara","year":"2018","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang YJ, Di Bartolomeo M, Mandal\u00e0 M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123\u201333.","journal-title":"Lancet"},{"key":"527_CR27","doi-asserted-by":"publisher","first-page":"4138","DOI":"10.1200\/JCO.20.01888","volume":"38","author":"T Kojima","year":"2020","unstructured":"Kojima T, Shah MA, Muro K, Francois E, Adenis A, Hsu C-H, et al. Randomized phase III KEYNOTE-181 study of pembrolizumab versus chemotherapy in advanced esophageal cancer. J Clin Oncol. 2020;38:4138\u201348.","journal-title":"J Clin Oncol"},{"key":"527_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1001\/jamaoncol.2020.3370","volume":"6","author":"K Shitara","year":"2020","unstructured":"Shitara K, van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and safety of pembrolizumab or pembrolizumab plus chemotherapy vs chemotherapy alone for patients with first-line, advanced gastric cancer: the KEYNOTE-062 phase 3 randomized clinical trial. JAMA Oncol. 2020;6:1571\u201380.","journal-title":"JAMA Oncol"},{"key":"527_CR29","doi-asserted-by":"publisher","first-page":"S1192","DOI":"10.1016\/j.annonc.2020.08.2298","volume":"31","author":"K Kato","year":"2020","unstructured":"Kato K, Sun J-M, Shah MA, Enzinger PC, Adenis A, Doi T, et al. LBA8_PR pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: the phase 3 KEYNOTE-590 study. Ann Oncol. 2020;31:S1192\u20133.","journal-title":"Ann Oncol"},{"key":"527_CR30","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1016\/S0140-6736(21)01234-4","volume":"398","author":"JM Sun","year":"2021","unstructured":"Sun JM, Shen L, Shah MA, Enzinger P, Adenis A, Doi T, et al. Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398:759\u201371.","journal-title":"Lancet"},{"key":"527_CR31","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M, Garrido M, Salman P, Shen L, et al. First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398:27\u201340.","journal-title":"Lancet"},{"key":"527_CR32","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1200\/JCO.21.01862","volume":"40","author":"JJ Zhao","year":"2022","unstructured":"Zhao JJ, Yap DWT, Chan YH, Tan BKJ, Teo CB, Syn NL, et al. Low programmed death-ligand 1-expressing subgroup outcomes of first-line immune checkpoint inhibitors in gastric or esophageal adenocarcinoma. J Clin Oncol. 2022;40:392\u2013402.","journal-title":"J Clin Oncol"},{"key":"527_CR33","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/SLA.0b013e3181d3d29b","volume":"251","author":"VE Strong","year":"2010","unstructured":"Strong VE, Song KY, Park CH, Jacks LM, Gonen M, Shah M, et al. Comparison of gastric cancer survival following R0 resection in the United States and Korea using an internationally validated nomogram. Ann Surg. 2010;251:640\u20136.","journal-title":"Ann Surg"},{"key":"527_CR34","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1200\/JCO.2015.62.6598","volume":"34","author":"JR Hecht","year":"2016","unstructured":"Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in combination with capecitabine plus oxaliplatin in human epidermal growth factor receptor 2-positive advanced or metastatic gastric, esophageal, or gastroesophageal adenocarcinoma: TRIO-013\/LOGiC: a randomized phase III trial. J Clin Oncol. 2016;34:443\u201351.","journal-title":"J Clin Oncol"},{"key":"527_CR35","doi-asserted-by":"publisher","first-page":"S1192","DOI":"10.1016\/j.annonc.2020.08.2297","volume":"31","author":"N Boku","year":"2020","unstructured":"Boku N, Ryu MH, Oh D-Y, Oh SC, Chung HC, Lee K-W, et al. LBA7_PR nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric\/gastroesophageal junction (G\/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study. Ann Oncol. 2020;31:S1192.","journal-title":"Ann Oncol"},{"key":"527_CR36","doi-asserted-by":"publisher","first-page":"S1329","DOI":"10.1016\/j.annonc.2021.08.2131","volume":"32","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Ajani JA, Moehler M, Garrido M, Gallardo C, Shen L, et al. LBA7 Nivolumab (NIVO) plus chemotherapy (Chemo) or ipilimumab (IPI) vs chemo as first-line (1L) treatment for advanced gastric cancer\/gastroesophageal junction cancer\/esophageal adenocarcinoma (GC\/GEJC\/EAC): CheckMate 649 study. Ann Oncol. 2021;32:S1329\u201330.","journal-title":"Ann Oncol"},{"key":"527_CR37","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1200\/JCO.20.00892","volume":"39","author":"M Moehler","year":"2021","unstructured":"Moehler M, Dvorkin M, Boku N, \u00d6zg\u00fcro\u011flu M, Ryu MH, Muntean AS, et al. Phase III trial of avelumab maintenance after first-line induction chemotherapy versus continuation of chemotherapy in patients with gastric cancers: results from JAVELIN Gastric 100. J Clin Oncol. 2021;39:966\u201377.","journal-title":"J Clin Oncol"},{"key":"527_CR38","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1038\/s41586-021-04161-3","volume":"600","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Kawazoe A, Ya\u00f1ez P, Li N, Lonardi S, Kolesnik O, et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600:727\u201330.","journal-title":"Nature"},{"key":"527_CR39","unstructured":"US FDA. FDA grants accelerated approval to pembrolizumab for HER2-positive gastric cancer. Available from: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-pembrolizumab-her2-positive-gastric-cancer. [Accessed 1 Mar 2022]."},{"key":"527_CR40","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"5","key":"527_CR41","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1016\/j.annonc.2021.02.004","volume":"32","author":"EC Smyth","year":"2021","unstructured":"Smyth EC, Gambardella V, Cervantes A, Fleitas T. Checkpoint inhibitors for gastroesophageal cancers: dissecting heterogeneity to better understand their role in first-line and adjuvant therapy. Ann Oncol. 2021;32(5):590\u20139.","journal-title":"Ann Oncol"},{"key":"527_CR42","doi-asserted-by":"publisher","first-page":"2074","DOI":"10.1056\/NEJMoa1112088","volume":"366","author":"P van Hagen","year":"2012","unstructured":"van Hagen P, Hulshof MCCM, van Lanschot JJB, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BPL, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366:2074\u201384.","journal-title":"N Engl J Med"},{"key":"527_CR43","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1016\/S1470-2045(15)00040-6","volume":"16","author":"J Shapiro","year":"2015","unstructured":"Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090\u20138.","journal-title":"Lancet Oncol"},{"key":"527_CR44","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, Zander T, Van Cutsem E, Piessen G, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. N Engl J Med. 2021;384:1191\u2013203.","journal-title":"N Engl J Med"},{"issue":"23","key":"527_CR45","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1056\/NEJMoa2017699","volume":"383","author":"T Andr\u00e9","year":"2020","unstructured":"Andr\u00e9 T, Shiu K-K, Kim TW, Jensen BV, Jensen LH, Punt C, et al. Pembrolizumab in microsatellite-instability-high advanced colorectal cancer. N Engl J Med. 2020;383(23):2207\u201318.","journal-title":"N Engl J Med"},{"key":"527_CR46","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s10120-016-0594-4","volume":"20","author":"R Giampieri","year":"2017","unstructured":"Giampieri R, Maccaroni E, Mandolesi A, Del Prete M, Andrikou K, Faloppi L, et al. Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapy. Gastric Cancer. 2017;20:156\u201363.","journal-title":"Gastric Cancer"},{"key":"527_CR47","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1001\/jamaoncol.2016.6762","volume":"3","author":"EC Smyth","year":"2017","unstructured":"Smyth EC, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z, et al. Mismatch repair deficiency, microsatellite instability, and survival: an exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) trial. JAMA Oncol. 2017;3:1197\u2013203.","journal-title":"JAMA Oncol"},{"key":"527_CR48","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.bulcan.2019.11.016","volume":"107","author":"R Cohen","year":"2020","unstructured":"Cohen R, Pudlarz T, Garcia-Larnicol M, Vernerey D, Dray X, Clavel L, et al. Localized MSI\/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: the GERCOR NEONIPIGA phase II study is opened to recruitment. Bull Cancer. 2020;107:438\u201346.","journal-title":"Bull Cancer"},{"key":"527_CR49","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.1126\/science.aaf1490","volume":"351","author":"N McGranahan","year":"2016","unstructured":"McGranahan N, Furness AJS, Rosenthal R, Ramskov S, Lyngaa R, Saini SK, et al. Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade. Science. 2016;351:1463\u20139.","journal-title":"Science"},{"key":"527_CR50","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1056\/NEJMc1713444","volume":"377","author":"M Yarchoan","year":"2017","unstructured":"Yarchoan M, Hopkins A, Jaffee EM. Tumor mutational burden and response rate to PD-1 inhibition. N Engl J Med. 2017;377:2500\u20131.","journal-title":"N Engl J Med"},{"key":"527_CR51","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","volume":"21","author":"A Marabelle","year":"2020","unstructured":"Marabelle A, Fakih M, Lopez J, Shah M, Shapira-Frommer R, Nakagawa K, et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353\u201365.","journal-title":"Lancet Oncol"},{"key":"527_CR52","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.annonc.2021.05.803","volume":"32","author":"K Shitara","year":"2021","unstructured":"Shitara K, \u00d6zg\u00fcro\u011flu M, Bang Y-J, Di Bartolomeo M, Mandal\u00e0 M, Ryu M-H, et al. Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase III trial in patients with gastroesophageal adenocarcinoma. Ann Oncol. 2021;32:1127\u201336.","journal-title":"Ann Oncol"},{"issue":"9","key":"527_CR53","doi-asserted-by":"publisher","first-page":"2168","DOI":"10.1158\/2159-8290.CD-21-0219","volume":"11","author":"M Kwon","year":"2021","unstructured":"Kwon M, An M, Klempner SJ, Lee H, Kim K-M, Sa JK, et al. Determinants of response and intrinsic resistance to PD-1 blockade in microsatellite instability-high gastric cancer. Cancer Discov. 2021;11(9):2168\u201385.","journal-title":"Cancer Discov"},{"key":"527_CR54","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1053\/j.gastro.2014.09.020","volume":"148","author":"SY Kim","year":"2015","unstructured":"Kim SY, Park C, Kim HJ, Park J, Hwang J, Kim J, et al. Deregulation of immune response genes in patients with Epstein-Barr virus-associated gastric cancer and outcomes. Gastroenterology. 2015;148:137\u201347.","journal-title":"Gastroenterology"},{"key":"527_CR55","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1136\/gutjnl-2013-304531","volume":"63","author":"M Constanza Camargo","year":"2014","unstructured":"Constanza Camargo M, Kim WH, Chiaravalli AM, Kim KM, Corvalan AH, Matsuo K, et al. Improved survival of gastric cancer with tumour Epstein-Barr virus positivity: an international pooled analysis. Gut. 2014;63:236\u201343.","journal-title":"Gut"},{"key":"527_CR56","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24:1449\u201358.","journal-title":"Nat Med"},{"key":"527_CR57","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40425-019-0514-3","volume":"7","author":"S Mishima","year":"2019","unstructured":"Mishima S, Kawazoe A, Nakamura Y, Sasaki A, Kotani D, Kuboki Y, et al. Clinicopathological and molecular features of responders to nivolumab for patients with advanced gastric cancer. J Immunother Cancer. 2019;7:1\u20138.","journal-title":"J Immunother Cancer"},{"key":"527_CR58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1097\/CJI.0000000000000316","volume":"43","author":"T Xie","year":"2020","unstructured":"Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C, et al. Positive status of Epstein\u2013Barr virus as a biomarker for gastric cancer immunotherapy: a prospective observational study. J Immunother. 2020;43:139\u201344.","journal-title":"J Immunother"},{"key":"527_CR59","doi-asserted-by":"crossref","unstructured":"Kennedy T, Shah MM, In H, Chuy JW, Moore DF, Kooby DA, et al. Preoperative pembrolizumab for MSI high, EBV positive or PD-L1 positive locally advanced gastric cancer followed by surgery and adjuvant chemoradiation with pembrolizumab: interim results of a phase 2 multi-center trial (NCT03257163). J Clin Oncol. 2021;39:e16111.","DOI":"10.1200\/JCO.2021.39.15_suppl.e16111"},{"issue":"18","key":"527_CR60","doi-asserted-by":"publisher","first-page":"2053","DOI":"10.1200\/JCO.19.03296","volume":"38","author":"S Fukuoka","year":"2020","unstructured":"Fukuoka S, Hara H, Takahashi N, Kojima T, Kawazoe A, Asayama M, et al. Regorafenib plus nivolumab in patients with advanced gastric (GC) or colorectal cancer (CRC): an open-label, dose-finding, and dose-expansion phase 1b trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;38(18):2053\u201361.","journal-title":"J Clin Oncol"},{"key":"527_CR61","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1016\/S1470-2045(20)30326-0","volume":"21","author":"DVT Catenacci","year":"2020","unstructured":"Catenacci DVT, Kang YK, Park H, Uronis HE, Lee KW, Ng MCH, et al. Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22\u201305): a single-arm, phase 1b\u20132 trial. Lancet Oncol. 2020;21:1066\u201376.","journal-title":"Lancet Oncol"},{"issue":"10","key":"527_CR62","first-page":"1155","volume":"17","author":"DV Catenacci","year":"2020","unstructured":"Catenacci DV, Rosales M, Chung HC, Yoon H, Shen L, Moehler M, et al. MAHOGANY: margetuximab combination in HER2+ unresectable\/metastatic gastric\/gastroesophageal junction adenocarcinoma. Future Med. 2020;17(10):1155\u201364.","journal-title":"Future Med"},{"key":"527_CR63","doi-asserted-by":"publisher","first-page":"S1040","DOI":"10.1016\/j.annonc.2021.08.1481","volume":"32","author":"C Qi","year":"2021","unstructured":"Qi C, Qin Y, Liu D, Gong J, Ge S, Zhang M, et al. 1372O CLDN 18.2-targeted CAR-T cell therapy in patients with cancers of the digestive system. Ann Oncol. 2021;32:S1040.","journal-title":"Ann Oncol"},{"key":"527_CR64","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2217\/fon-2020-0969","volume":"17","author":"MA Shah","year":"2021","unstructured":"Shah MA, Bennouna J, Doi T, Shen L, Kato K, Adenis A, et al. KEYNOTE-975 study design: a phase III study of definitive chemoradiotherapy plus pembrolizumab in patients with esophageal carcinoma. Future Oncol. 2021;17:1143\u201353.","journal-title":"Future Oncol"},{"key":"527_CR65","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS373","volume":"40","author":"L Wang","year":"2022","unstructured":"Wang L, Chen M, Kato K, Wyrwicz L, Smyth EC, Jiang A, et al. A phase 3 randomized, double-blind, placebo-controlled, multicenter, global study of durvalumab with and after chemoradiotherapy in patients with locally advanced, unresectable esophageal squamous cell carcinoma: KUNLUN. J Clin Oncol. 2022;40:373.","journal-title":"J Clin Oncol"},{"key":"527_CR66","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1200\/JCO.2022.40.4_suppl.TPS374","volume":"40","author":"KA Goodman","year":"2022","unstructured":"Goodman KA, Xu R, Chau I, Chen MH, Cho BC, Shah MA, et al. SKYSCRAPER-07: a phase III, randomized, double-blind, placebo-controlled study of atezolizumab with or without tiragolumab in patients with unresectable ESCC who have not progressed following definitive concurrent chemoradiotherapy. J Clin Oncol. 2022;40:374.","journal-title":"J Clin Oncol"}],"updated-by":[{"DOI":"10.1007\/s40259-022-00535-9","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T00:00:00Z","timestamp":1650844800000}},{"DOI":"10.1007\/s40259-022-00560-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2022,10,15]],"date-time":"2022-10-15T00:00:00Z","timestamp":1665792000000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-022-00527-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-022-00527-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T08:24:59Z","timestamp":1666599899000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-022-00527-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,6]]},"references-count":66,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["527"],"URL":"https:\/\/doi.org\/10.1007\/s40259-022-00527-9","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,6]]},"assertion":[{"value":"7 March 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 April 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2022","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40259-022-00560-8","URL":"https:\/\/doi.org\/10.1007\/s40259-022-00560-8","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 April 2022","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40259-022-00535-9","URL":"https:\/\/doi.org\/10.1007\/s40259-022-00535-9","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No external funding was used in the preparation of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"ECS declares honoraria for advisory roles from Amal Therapeutics, Aptitude Health, Astellas, Astra Zeneca, Beigene, BMS, Celgene, Elsevier, Everest Clinical Research, First Word Group, Five Prime Therapeutics, Gritstone Oncology, Imedex, Merck, My Personal Therapeutics, Novartis, Roche, Sai-Med, Servier and Zymeworks. MEB declares that they have no conflicts of interest that might be relevant to the contents of this article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}}]}}